Impact of Residual Nodal Disease Burden on Technical Outcomes of Sentinel Lymph Node Biopsy for Node-Positive (cN1) Breast Cancer Patients Treated with Neoadjuvant ChemotherapyAlison Laws, Tari A. King, Melissa E. Hughes et al.|Annals of Surgical Oncology|2019Cited by 29
TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancerFilipa Lynce, Kornélia Polyák, Antonio C. Wolff et al.|Breast Cancer Research|2024Cited by 22
Multidisciplinary Management of the Axilla in Patients with cT1-T2 N0 Breast Cancer Undergoing Primary Mastectomy: Results from a Prospective Single-Institution SeriesSamantha Grossmith, Tari A. King, Anvy Nguyen et al.|Annals of Surgical Oncology|2018Cited by 19
How Often Does Retrieval of a Clipped Lymph Node Change Adjuvant Therapy Recommendations? A Prospective, Consecutive, Patient Cohort StudyAnna Weiss, Tari A. King, Samantha Grossmith et al.|Annals of Surgical Oncology|2022Cited by 17
Impact of residual nodal disease burden on sentinel node mapping and accuracy of intraoperative frozen section in node positive (cN1) breast cancer patients treated with neoadjuvant chemotherapy (NAC).Alison Laws, Tari A. King, Melissa E. Hughes et al.|Journal of Clinical Oncology|2018Cited by 1